Takaya Yamamoto

Lower lobe origin was independently associated with poorer survival in patients with stage III NSCLC treated with CCRT followed by consolidation durvalumab, suggesting that primary tumor location may provide additional prognostic information, although its implications for treatment or surveillance strategies require further investigation.